Rockefeller University Press

Table I

Virology, cell selection, treatment, and immune recovery data

	Clinical details							Selection data
Patient	Primary  diagnosis	Transplant  protocol	Day cells  infused	ALC at infusion	Specificity  infused	Total cells  infused/kg	Purity	Day after  infusion  of CTL peak	Peak  CTL	Maximum  grade  of GvHD	Antiviral  administration
				× 10⁹L			% CD3⁺ cells		tetramer⁺ cells/μl
1	WM	BC	40	0.1	NLV	3.1 × 10³	98.5	12	8.4	0	yes
2	AML	FMC	18	0.3	YSE	1.47 × 10⁴	92.6	18	156	0	no
3	CLL	FMC	23	1.1	YSE	3.1 × 10³	95.6	19	42	0	no
4	CML	Cy, TBI	34	0.8	YSE + ELR	1.23 × 10³	99.5	16	15	II	yes
5	HD	FMC	29	0.4	TPR + NLV	1.67 × 10³	88.0	27	44	I	no
6	CML	Cy, Bu	55	0.6	NLV	8.6 × 10³	98.0	4	101	0	no
7^{^a}	CML	Cy, TBI	246	1.2	NLV	3.3 × 10⁴	99.2	6	2	0	pretherapy
8^{^a}	ALL	Cy, TBI	247	0.55	IPS	1.22 × 10⁴	10^{^b}	26	1.1	0	pretherapy
9	ALL	FMC	21	0.2	ELR	1.0 × 10⁴	95.4	114	105	II	pretherapy

	Clinical details							Selection data
Patient	Primary  diagnosis	Transplant  protocol	Day cells  infused	ALC at infusion	Specificity  infused	Total cells  infused/kg	Purity	Day after  infusion  of CTL peak	Peak  CTL	Maximum  grade  of GvHD	Antiviral  administration
				× 10⁹L			% CD3⁺ cells		tetramer⁺ cells/μl
1	WM	BC	40	0.1	NLV	3.1 × 10³	98.5	12	8.4	0	yes
2	AML	FMC	18	0.3	YSE	1.47 × 10⁴	92.6	18	156	0	no
3	CLL	FMC	23	1.1	YSE	3.1 × 10³	95.6	19	42	0	no
4	CML	Cy, TBI	34	0.8	YSE + ELR	1.23 × 10³	99.5	16	15	II	yes
5	HD	FMC	29	0.4	TPR + NLV	1.67 × 10³	88.0	27	44	I	no
6	CML	Cy, Bu	55	0.6	NLV	8.6 × 10³	98.0	4	101	0	no
7^{^a}	CML	Cy, TBI	246	1.2	NLV	3.3 × 10⁴	99.2	6	2	0	pretherapy
8^{^a}	ALL	Cy, TBI	247	0.55	IPS	1.22 × 10⁴	10^{^b}	26	1.1	0	pretherapy
9	ALL	FMC	21	0.2	ELR	1.0 × 10⁴	95.4	114	105	II	pretherapy

Patient 7 had been refractory to ganciclovir and patient 8 had been refractory to cidofovir.

Purity was reduced due to the low frequency of the CMV-specific CD8⁺ T cells in the donor (0.08% of CD8⁺ cells). The depletion of cells not binding tetramer was >3 log. CMV epitopes are as follows: ELR-IE1_199-207; IPS-pp65_123-131; NLV – pp65_495-503; TPR-pp65_417-426; YSE-pp65_363-373.

ALC, absolute lymphocyte count; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, BEAM/Campath-1H; Bu, busulfan; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; Cy, cyclophosphamide; FMC, fludarabine melphalan Campath-1H; HD, Hodgkin's disease; TBI, total body irradiation; WM, Waldenström's macroglobulinemia.

View Large

This Feature Is Available To Subscribers Only